All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-SARZP29 | Anti-SARS-CoV-2 (COVID-19) S (S227.14) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | S227.14 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP30 | Anti-SARS-CoV-2 (COVID-19) S (S227.14) h(4-1BB-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | S227.14 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP31 | Anti-SARS-CoV-2 (COVID-19) S (508-573) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | 508-573 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP32 | Anti-SARS-CoV-2 (COVID-19) S (508-573) h(4-1BB-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | 508-573 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP41 | Anti-SARS-CoV-2 (COVID-19) S (508-104) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | 508-104 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP42 | Anti-SARS-CoV-2 (COVID-19) S (508-104) h(4-1BB-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | 508-104 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP43 | Anti-SARS-CoV-2 (COVID-19) S (508-68) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | 508-68 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP44 | Anti-SARS-CoV-2 (COVID-19) S (508-68) h(4-1BB-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | 508-68 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP45 | Anti-SARS-CoV-2 (COVID-19) S (508-39) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | 508-39 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP101 | Anti-SARS-CoV-2 (COVID-19) S (S128.5) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | S128.5 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP102 | Anti-SARS-CoV-2 (COVID-19) S (S128.5) h(4-1BB-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | S128.5 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP103 | Anti-SARS-CoV-2 (COVID-19) S (S132.9) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | S132.9 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP104 | Anti-SARS-CoV-2 (COVID-19) S (S132.9) h(4-1BB-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | S132.9 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP167 | Anti-SARS-CoV-2 (COVID-19) S (47D11) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | 47D11 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP168 | Anti-SARS-CoV-2 (COVID-19) S (47D11) h(4-1BB-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | 47D11 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP169 | Anti-SARS-CoV-2 (COVID-19) S (n3130) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | n3130 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP170 | Anti-SARS-CoV-2 (COVID-19) S (n3130) h(4-1BB-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | n3130 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP171 | Anti-SARS-CoV-2 (COVID-19) S (n3088) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | n3088 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP172 | Anti-SARS-CoV-2 (COVID-19) S (n3088) h(4-1BB-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | n3088 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-SARZP173 | Anti-SARS-CoV-2 (COVID-19) S (S309) h(CD28-CD3ζ) CAR, pCDCAR1 | SARS-CoV-2 (COVID-19) | S309 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T Cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION